4-氧代-3,4-二氢-2H-吡喃-2-羧酸乙酯 | 287193-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃
• 中文名称: 4-氧代-3,4-二氢-2H-吡喃-2-羧酸乙酯
• 英文名称: ethyl 4-oxo-3,4-dihydro-2H-pyran-2-carboxylate
• 英文别名: 2-ethoxyformyl-2,3-dihydro-4H-pyran-4-one；ethyl 4-oxo-2,3-dihydropyran-2-carboxylate
• CAS: 287193-06-0
• 化学式: C₈H₁₀O₄
• mdl: MFCD20922880
• 分子量: 170.165
• InChiKey: IAAASNBKIHCSJH-UHFFFAOYSA-N

物化性质

• 沸点：
  242.8±29.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  4-氧代-3,4-二氢-2H-吡喃-2-羧酸乙酯 在 钯 氢气 、 silica gel 作用下， 以 乙酸乙酯 为溶剂， 反应 4.0h， 以to give 4-oxo-tetrahydro-pyran-2-carboxylic acid ethyl ester (2.62 g, 33% yield) as an oil的产率得到4-氧代四氢-2H-吡喃-2-羧酸乙酯
  参考文献：
  名称：

  SERINE/THREONINE KINASE INHIBITORS

  摘要：

  提供了化学式I或其立体异构体、互变异构体、前药或药物可接受的盐的化合物，其可用于治疗过度增殖、疼痛和炎症性疾病。公开了使用化学式I或其立体异构体、互变异构体、前药或药物可接受的盐的化合物，用于哺乳动物细胞中的体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件的方法。

  公开号：

  US20140249127A1
• 作为产物：
  描述：

  乙醛酸乙酯 、 反-1-甲氧基-3-(三甲基硅氧基)-1,3-丁二烯 在 [(R,R)-N,N'-bis(3,5-di-tert-butylsalicylidene)-1,2-cyclo-hexanediaminato^(2-)]Mn(II)sulfophenyl-D-sodum lactose templated helical silica supported 作用下， 以 二氯甲烷 为溶剂， 反应 6.0h， 以100%的产率得到4-氧代-3,4-二氢-2H-吡喃-2-羧酸乙酯
  参考文献：
  名称：

  Highly asymmetric hetero-Diels–Alder reaction using helical silica-supported Mn(III)-salen catalysts

  摘要：

  Helical silica were prepared and functionalized by Mn(III)-salen complexes in order to catalyze asymmetric hetero-Diels Alder reactions. Characterizations revealed doping of sodium lactate facilitated porosity, hydrolysis resistance and chiral configuration of silica matrix. Catalysis revealed the combination of Mn(III)-salen with helical silica had excellent chiral induction. Major product configuration was affected by temperature and solvent. Loading imidazolium ionic liquid as solvent improved both enantioselectivity and catalyst recycling. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2015.08.045

文献信息

• [EN] SERINE/THREONINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA SÉRINE / THRÉONINE KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2013130976A1

  公开（公告）日：2013-09-06

  Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  提供了公式I或其立体异构体、互变异构体、前药或药用盐，这些化合物可用于治疗高增殖、疼痛和炎症性疾病。公开了使用公式I或其立体异构体、互变异构体、前药或药用盐在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗这些疾病或相关病理状况的方法。
• Substituted bicyclic derivatives useful as anticancer agents
  申请人：——

  公开号：US20010034351A1

  公开（公告）日：2001-10-25

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R 1 , R 3 and R 4 are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals with administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及公式11的化合物及其药学上可接受的盐和溶剂化物，其中A、X、R1、R3和R4的定义如本文所述。本发明还涉及使用公式1的化合物治疗哺乳动物中的异常细胞生长的方法，并涉及含有公式1的化合物的治疗此类疾病的制药组合物。本发明还涉及制备公式1的化合物的方法。
• Method of inhibiting protein tyrosine phosphatase 1B and/or T-cell protein tyrosine phosphatase 4 and/or other PTPases with an Asp residue at position 48
  申请人：Novo Nordisk A/S

  公开号：US07115624B1

  公开（公告）日：2006-10-03

  The present invention provides a method of inhibiting a member of a family of Protein Tyrosine Phosphatases (PTPases, PTPs) such as PTP1B, TC-PTP, CD45, SHP-1, SHP-2, PTPα, PTPε, PTPμ, PTPδ, PTPσ, PTPζ, PTPβ, PTPD1, PTPD2, PTPH1, PTP-MEG1, PTP-LAR, and HePTP by exposing said Ptpase member by administration to a host or otherwise to at least one compound with certain structural, physical and spatial characteristics that allow for the interaction of said compound with specific residues of the active site of PTP1B and/or TC-PTP. These compounds are indicated in the management or treatment of a broad range of diseases such as autoimmune diseases, acute and chronic inflammation, osteoporosis, various forms of cancer and malignant diseases, and type I diabetes and type II diabetes, as well as in the isolation of PTPases and in elucidation or further elucidation of their biological function.

  本发明提供了一种抑制蛋白酪氨酸磷酸酶（PTPases，PTPs）家族成员（如PTP1B、TC-PTP、CD45、SHP-1、SHP-2、PTPα、PTPε、PTPμ、PTPδ、PTPσ、PTPζ、PTPβ、PTPD1、PTPD2、PTPH1、PTP-MEG1、PTP-LAR和HePTP）的方法，通过将至少一种具有特定结构、物理和空间特征的化合物与PTP1B和/或TC-PTP的活性位点上的特定残基相互作用，使该PTPase成员暴露于宿主或以其他方式进行管理或治疗。这些化合物适用于管理或治疗广泛的疾病，如自身免疫性疾病、急性和慢性炎症、骨质疏松症、各种癌症和恶性疾病、1型糖尿病和2型糖尿病，以及在PTPases的分离和阐明或进一步阐明其生物学功能方面。
• Serine/threonine kinase inhibitors
  申请人：Array BioPharma Inc.

  公开号：US08697715B2

  公开（公告）日：2014-04-15

  Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  提供了公式I的化合物或其立体异构体、互变异构体、前药或药学上可接受的盐，用于治疗过度增殖、疼痛和炎症性疾病。本文还揭示了使用公式I的化合物或其立体异构体、互变异构体、前药或药学上可接受的盐的方法，用于哺乳动物细胞中的体外、体内和原位诊断、预防或治疗此类疾病或相关病理条件。
• IRAK INHIBITORS AND USES THEREOF
  申请人：NIMBUS IRIS, INC.

  公开号：US20130231328A1

  公开（公告）日：2013-09-05

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。